ArticleRice (New York, N.Y.)2026
Establishment of a Non-transgenic Iron-Biofortified Rice Line Using a Novel HRZ1 Mutation.
Article in Rice (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron (Fe) deficiency anemia is a significant public health problem worldwide. The development of Fe biofortification in staple food crops, such as rice, through non-transgenic methods is highly anticipated to enhance broad applicability. In this study, we isolated a high Fe-accumulating mutant (tetsu) from an N-methyl-N-nitrosourea (MNU) mutagenized ‘Taichung-65 (T65)’ rice population. The tetsu mutant accumulated more than 3-fold higher levels of Fe and significantly higher levels of manganese (Mn) and nickel (Ni) in the shoot than the wild-type (WT) T65, whereas the levels of toxic heavy metals such as cadmium (Cd), lead (Pb), and cobalt (Co) were comparable to those of the WT. In both polished and brown rice of the tetsu mutant, Fe increased by approximately 2-fold, and Zn and Cu also significantly increased compared with those in T65. Perls’ staining revealed that Fe localization in rice grains was not limited to the outer layers and scutellum, but also extended into the endosperm of the tetsu mutant. Concomitant with high Fe accumulation, the tetsu mutant showed remarkable tolerance to alkaline Fe-deficient soil conditions. Genotyping by Random Amplicon Sequencing-Direct (GRAS-Di) analysis revealed a novel nonsense mutation in the Hemerythrin motif-containing Ring Zinc-finger protein 1 (HRZ1) gene in the tetsu genome, which is known to govern the negative regulation of the Fe deficiency response and is crucial for normal development. The homozygous tetsu mutation leads to a substantial increase in shoot Fe content, alongside the upregulation of several genes related to Fe uptake and translocation, without causing serious adverse effects on growth. To utilize this novel mutation in Fe-biofortified rice breeding, we created recombinant inbred lines (RILs) derived from crosses between the tetsu mutant and ‘Asamurasaki,’ a nutrient-rich black rice cultivar. During the breeding process, we successfully selected RILs that exhibited normal growth and fertility, resulting in the development of non-transgenic Fe-biofortified rice lines with various waxy/glutinous properties and polyphenol content in brown rice for versatile applications. These results indicate that the identified novel HRZ1 mutation is a valuable target for engineering non-transgenic Fe-biofortified rice cultivars with various beneficial traits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.